Leerink Partners Remains Bullish as Teva Pharma (TEVA) Awaits IPR Ruling

August 15, 2016 2:00 PM EDT
Get Alerts TEVA Hot Sheet
Price: $32.60 -0.34%

Rating Summary:
    18 Buy, 21 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 19 | Down: 19 | New: 13
Trade TEVA Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Leerink Partners reiterated an Outperform rating and $66.00 price target on Teva Pharma (NYSE: TEVA) ahead of an IPR ruling on three TEVA patents.

Analyst Jason Gerberry commented, "We continue to eagerly await the IPR (inter partes review) ruling on three TEVA patents that cover Copaxone 40mg (multiple sclerosis). Today's post grant review (PGR) decision not to review the '776 patent further strengthens TEVA’s broader IP defense strategy, but the PTAB opinion did not address any of the substantive issues relating to the IPR ruling which will occur on or before 8/25."

For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.

Shares of Teva Pharma closed at $53.86 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Add Your Comment